Literature DB >> 9106050

Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies.

S D Jayaraman1, S Ismail, N K Nair, V Navaratnam.   

Abstract

A method is described for the determination of pyronaridine in plasma using high-performance liquid chromatography with fluorescence detection. The method involves liquid-liquid extraction with phosphate buffer (pH 6.0, 0.05 M) and diethyl ether-hexane (70:30%, v/v) and chromatographic separation on a C18 column (Nucleosil, 250 x 4.6 mm I.D., 5 microns particle size) with acetonitrile-0.05 M phosphate buffer pH 6.0 (60:40%, v/v) as the mobile phase (1 ml/min) and detection by fluorescence (lambda ex = 267 nm, lambda em = 443 nm). The detector response is linear up to 1000 ng and the overall recoveries of pyronaridine and quinine were 90.0 and 60.3%, respectively. The assay procedure was adequately sensitive to measure 10 ng/ml pyronaridine in plasma samples with acceptable precision (< 15% C.V.). The method was found to be suitable for use in clinical pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106050     DOI: 10.1016/s0378-4347(96)00410-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  7 in total

1.  Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Alexander N Freiberg; Huanying Zhou; Julie Dyall; Michael R Holbrook; Manu Anantpadma; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  Antiviral Res       Date:  2020-07-16       Impact factor: 5.970

2.  Pyronaridine Protects against SARS-CoV-2 Infection in Mouse.

Authors:  Ana C Puhl; Giovanni F Gomes; Samara Damasceno; Andre S Godoy; Gabriela D Noske; Aline M Nakamura; Victor O Gawriljuk; Rafaela S Fernandes; Natalia Monakhova; Olga Riabova; Thomas R Lane; Vadim Makarov; Flavio P Veras; Sabrina S Batah; Alexandre T Fabro; Glaucius Oliva; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Sean Ekins
Journal:  ACS Infect Dis       Date:  2022-05-24       Impact factor: 5.578

3.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

4.  Development of antimalarial drugs and their application in China: a historical review.

Authors:  Chang Chen
Journal:  Infect Dis Poverty       Date:  2014-03-20       Impact factor: 4.520

5.  Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding.

Authors:  Daniel Blessborn; Karnrawee Kaewkhao; Lijiang Song; Nicholas J White; Nicholas P J Day; Joel Tarning
Journal:  J Pharm Biomed Anal       Date:  2017-08-26       Impact factor: 3.935

6.  Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.

Authors:  Matthias Rottmann; Brian Jonat; Christin Gumpp; Satish K Dhingra; Marla J Giddins; Xiaoyan Yin; Lassina Badolo; Beatrice Greco; David A Fidock; Claude Oeuvray; Thomas Spangenberg
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

7.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.